SCHEMBL16666447

SCHEMBL16666447

C[C@@H](OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UBASH3B Q8TF42 1/20 0.68
▸ TACR1 P25103 6/20 0.49
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ F11 P03951 2/20 0.45
▸ CCKBR P32239 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ PTGS2 P35354 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ LNPEP Q9UIQ6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17268610 0.88 UBASH3B (0.75) UBASH3BTACR1KDM4EALDH1A1PKM
SCHEMBL16666855 0.85 UBASH3B (0.79) UBASH3BTACR1KDM4EALDH1A1PKM
SCHEMBL16666448 0.84 UBASH3B (0.69) UBASH3BTACR1KDM4EALDH1A1PKM
SCHEMBL16666450 0.84 UBASH3B (0.69) UBASH3BTACR1KDM4EALDH1A1PKM
SCHEMBL16666555 0.83 UBASH3B (0.76) UBASH3BTACR1KDM4EALDH1A1PKM
SCHEMBL16666339 0.83 UBASH3B (0.68) UBASH3BTACR1KDM4EALDH1A1PKM
Rebamipide SCHEMBL23346201 0.82 UBASH3B (1.00) UBASH3BTACR1F11CCKBRPPARG
Rebamipide SCHEMBL221527 0.82 UBASH3B (1.00) UBASH3BTACR1F11CCKBRPPARG
Rebamipide SCHEMBL5794018 0.82 UBASH3B (1.00) UBASH3BTACR1F11CCKBRPPARG
Rebamipide SCHEMBL21623658 0.82 UBASH3B (1.00) UBASH3BTACR1F11CCKBRPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US claimed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP claimed
EP-2865669-B1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF SAMJIN PHARM CO LTD (KR) 2021-04-28 — — EP disclosed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US disclosed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF REV1, GRPR, SI UBASH3B 2690/4885TACR1 2155/4885KDM4E 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback